Chips, cells and computer models: regulators set out to replace animal testing
What happened
On 1 October 2026, the Medicines and Healthcare products Regulatory Agency announced that it had joined medicines regulators around the world in calling for alternatives to animal testing to be advanced and put into use. The MHRA is the UK body that decides whether a medicine can be sold here, and watches over its safety afterwards. The call takes the form of a joint statement. It was adopted at a plenary meeting of the International Coalition of Medicines Regulatory Authorities, usually shortened to ICMRA. That is a group that brings together medicines regulators from many countries. The statement was led by four agencies: the European Medicines Agency, the MHRA, Ireland's Health Products Regulatory Authority and Swissmedic, the Swiss regulator. The ambition is broad. The statement sets a long-term goal of replacing animal testing at every stage of a medicine's life. That means initial screening of possible drugs, early development, non-clinical testing, the licensing decision itself, and the checks that continue after a medicine is approved. It asks medicine developers to use non-animal methods where those methods are already acceptable to regulators, while keeping scientific quality high. It asks regulators to support that shift. One specific area is singled out. Batch release testing is the checking done on each manufactured batch of a product before it can be sold. The statement asks regulators to encourage non-animal batch release tests, and says animal testing for batch release should only be approved where there is strong scientific justification that no equal or better non-animal method exists. The MHRA notes it took related action earlier, in March 2026, and has published guidance on assessing applications that use what are called New Approach Methodologies. Those include organ-on-a-chip devices, computer models driven by artificial intelligence, and 3D bioprinted tissues.
Why this matters
Animal testing in medicine development is one of those subjects where two strong arguments meet. On one side, animal studies have been part of how medicines are made safe for over a century. Regulators have historically required them before a new drug is given to a person. On the other side, many people find animal testing ethically troubling. And there is a practical criticism too: animals are not people. A drug that behaves well in a mouse can still fail or cause harm in humans. Plenty of drugs have. What has changed is the technology. Organ-on-a-chip devices are small plastic or glass units containing living human cells arranged to mimic how a real organ behaves. Computer models trained on large amounts of biological data can predict how a chemical might behave in the body. 3D bioprinting can build small pieces of human tissue to test on. None of these replaces everything. But together they are starting to answer questions that previously needed an animal. The reason a regulator's view matters so much is simple. Drug developers do what regulators require. If regulators keep asking for animal data, companies will keep producing it, whatever the alternatives can do. A coordinated signal from several major regulators at once is how that changes. For patients, the hoped-for benefit is not only ethical. Better prediction of human effects earlier could mean fewer late failures and fewer unpleasant surprises.
What the evidence actually says
It is worth being realistic about what this announcement is. It is a statement of intent, not a change in the law. No UK rule changed on 1 October 2026. Nobody has banned anything. The statement sets a direction and asks developers and regulators to move in it. The wording is also carefully hedged, and sensibly so. It asks for non-animal methods to be used where they are "acceptable in regulatory contexts" and where scientific quality can be maintained. That is an important condition. A method that is kinder but less reliable would be a bad trade: it would put patients at risk. The statement is clearest where the science is clearest. For some classes of medicine, it notes, there is already no scientific justification for animal studies. Generic medicines and follow-on biological products are examples, because the original product has already been tested. The same logic can apply where an effect simply cannot be reproduced in any animal species. The long-term goals named include fully ending animal use in general toxicity studies, reproductive toxicity studies, carcinogenicity studies, and studies of how a drug acts and moves through the body. Those are ambitions, not deadlines. On the UK side, the MHRA's guidance on New Approach Methodologies is the practical part. It tells companies how the regulator will look at an application that uses these newer techniques. That is the step that turns intent into something a developer can act on. So the honest reading is: a meaningful signal from serious institutions, with the hard work of validation still ahead.
Practical advice
This is a policy story rather than something that changes your week, but there are a few things worth knowing. Nothing about your medicines has changed. Everything on a UK pharmacy shelf or in your repeat prescription was approved under the rules that applied at the time, and continues to be monitored. If you have an ethical concern about animal testing, the useful place to put energy is in supporting research into alternatives, rather than in avoiding medicines. Stopping a prescribed medicine on ethical grounds can be dangerous. Talk to your pharmacist or GP if this troubles you; they can discuss options without judgement. Be careful with claims on consumer products. "Not tested on animals" on a cosmetic or supplement is not the same thing as a medicine's safety testing, and the rules are different. Supplements are not tested the way medicines are at all. If you work in science, healthcare or a related field, the MHRA's guidance on New Approach Methodologies is publicly available and worth reading before designing a study. And if you want to follow this properly, go to the source. The MHRA publishes its news on GOV.UK, and the European Medicines Agency publishes the joint statement and related material on its own site. Both are free to read.
What to know
On 1 October 2026, the MHRA joined medicines regulators worldwide in a joint statement calling for alternatives to animal testing to be advanced across the whole life of a medicine, from early screening to post-approval checks. The statement was adopted at an ICMRA plenary and was led by the European Medicines Agency, the MHRA, Ireland's HPRA and Swissmedic. It asks developers to use non-animal methods where regulators already accept them, and asks regulators to support this. Batch release testing is highlighted: animal testing for batch release should only be approved where there is strong scientific justification that no equal or better alternative exists. This is a statement of direction rather than a change in law. The MHRA has separately published guidance on New Approach Methodologies, which include organ-on-a-chip devices, AI-driven predictive models and 3D bioprinted tissues. Nothing about current UK medicines or prescriptions changes as a result. Sources: Medicines and Healthcare products Regulatory Agency, "MHRA joins global regulators in call to advance alternatives to animal testing", GOV.UK, 1 October 2026, https://www.gov.uk/government/news/mhra-joins-global-regulators-in-call-to-advance-alternatives-to-animal-testing ; European Medicines Agency, "Global regulators call for advancing alternatives to animal testing across the medicine lifecycle", https://www.ema.europa.eu/en/news/global-regulators-call-advancing-alternatives-animal-testing-across-medicine-lifecycle ; Regulatory Affairs Professionals Society, "ICMRA joins call to replace animal testing with alternative approaches", https://www.raps.org/resource/icmra-joins-call-to-replace-animal-testing-with-alternative-approaches.html This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional. Never stop or change a prescribed medicine without speaking to a professional first.
Related articles
Four months early: 3,880 rural premises and an £8.2 million contract
On 13 October 2026, the government announced that a rural broadband project in North Oxfordshire had finished four months ahead of schedule. The work connected…
First hearing from a police cell: £17.4 million and four force areas
On 12 October 2026, the Ministry of Justice published the government's response to Lord Leveson's review of the criminal courts. The review made 180 recommendat…
Over 1,000 weak spots found, and a minister's message to AI firms
On Monday 12 October 2026, the UK government set out a package of measures aimed at protecting the country from increasingly powerful artificial intelligence.…